Op-Ed: The best way to capitalize on the potential revenue influx from enterprise-level drug adherence programs is to create room at the executive table for a Chief Adherence Officer.
Outside of raising prices, pharma can generate new revenue from just three other sources, write Tom Kottler.
Addressing adherence with c-suite sponsorship and at scale has the capacity increase revenue, improve patient outcomes and lower health care costs, writes Tom Kottler.